Certara Inc CERT

$9.60 +0.36 (3.90%)

Valuation

Market cap
1,409,460,000
Revenue TTM
$418,840,000
Net income TTM
$-1,600,000
PE ratio
38.04
Forward PE
40.88
Profit margin
-0.38%
Debt to equity
0.30

Trading

Volume
2,905,600
Avg volume
2,926,400
Day's range
$9.26 – $9.90
Shares out
152,539,000
Stochastic %K
63%
Beta
1.42
Analysts
Sell
Price target
$8.62

Price

Company profile

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp...

Show more

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Industry
Health Information Services
Sector
Healthcare
Phone
415 237 8272
Website
https://www.certara.com
Address
4 Radnor Corporate Center, Suite 350, Radnor, United States

Latest news

Stocktwits

Merlintrader Oct 11, 3:53 PM
In its August 4 update, Certara reported modest continuing-operations growth and a new buyback authorization. Execution remains the test. Certara $CERT: Biosimulation, Growth And Cash Flow https://www.merlintrader.com/certara-stock-hub/
0 replies
BioTechHealthX Sep 12, 1:30 PM
$CERT Certara combines AI, biosimulation and regulatory software to improve drug development. Could stronger software growth spark a recovery for CERT stock? https://biotechhealthx.com/biotech-news/certara-cert-is-under-8-is-this-quiet-ai-healthcare-play-ready-to-wake-up/
0 replies
BioTechHealthX Sep 6, 6:25 PM
$CERT $GEHC $RDNT $TEM $BFLY Looking for the best AI medicine stocks? These 5 companies are applying artificial intelligence to some of healthcare’s most valuable markets. https://biotechhealthx.com/biotech-news/5-best-cheap-ai-medicine-stocks-to-buy-now/
0 replies
BioGem Aug 9, 9:57 PM
$CERT This may be shortable soon. Extremely overvalued with critical negatives: -Missed both top and bottom lines. -No growth whatsoever now nor per their tepid and flat guidance. -Continued bottom line losses. -Negative free cash flow. -Huge and expensive debt. -Most importantly: ruthless competition from dozens of similar companies, or from AI models (Claude) that allow bio-simulation to be produced locally by each biotech company itself without needing CERT's services and programs. -Huge short interest = consensus of poor stock performance. -No prestigious biotech fund is invested.
1 replies
IDrawLiness Aug 8, 11:17 PM
$CERT Rejected several times at the 50EMA but holy cow look at that volume. Buyers closed out a great week. Long.
0 replies
Gundam2168 Aug 6, 9:34 PM
$BULL $CERT What Caused This Spike?This specific type of late-day trading behavior usually points to two common institutional mechanics rather than retail hype:Market-on-Close (MOC) Institutional Orders: Large mutual funds and index trackers accumulate shares throughout the day but mandate that their final executions take place exactly at the official closing price to minimize tracking error.Short-Covering Into Strength: With short interest sitting exceptionally high on the public float, short sellers who wanted to de-risk ahead of the Friday session likely bought blocks at the close to avoid getting trapped over the weekend.The heavy buying allowed the stock to close strong at $8.13, establishing a solid immediate support shelf after its post-earnings volatility earlier in the week.
0 replies
Gundam2168 Aug 6, 9:33 PM
$BULL $CERT Breaking Down the Last 30 Minutes of TradingThe data highlights a clear shift from quiet, baseline algorithmic trading to institutional block orders during the market close:12:30 PM – 12:50 PM (PDT): Trading was extremely quiet. Volume hovered between a tiny 7,700 and 32,500 shares per 5-minute interval, with the stock pinned flat around $8.06 to $8.07.12:55 PM (PDT): Momentum began to turn as a wave of buying absorbed 166,136 shares, pushing the stock price up from $8.09 to $8.13.1:00 PM Closing Candle (PDT): A massive block order hit the tape, executing 2,620,034 shares right at the closing bell. This single 5-minute window accounted for a significant portion of the entire day's market liquidity.
0 replies
Gundam2168 Aug 6, 9:32 PM
$BULL $CERT Here's what I found for CERT: there was a massive surge of heavy buying in the final 10 minutes of the trading session today.Intraday transaction logs show that trading volume spiked dramatically right before the closing bell, driving a micro-breakout in Certara's stock price.
0 replies